MIM
RLAY icon

MetLife Investment Management’s Relay Therapeutics RLAY Stock Holding History

MetLife Investment Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
94,122
+15,098
+19% +$219K 0.01% 1232
2026
Q1 		$786K Buy
79,024
+1,488
+2% +$13.3K ﹤0.01% 1515
2025
Q4 		$656K Buy
77,536
+14,321
+23% +$102K ﹤0.01% 1666
2025
Q3 		$330K Sell
63,215
-11,902
-16% -$45.4K ﹤0.01% 2026
2025
Q2 		$260K Buy
75,117
+9,845
+15% +$29.3K ﹤0.01% 2040
2025
Q1 		$171K Sell
65,272
-8,894
-12% -$34.8K ﹤0.01% 2278
2024
Q4 		$306K Buy
74,166
+16,477
+29% +$89.7K ﹤0.01% 2065
2024
Q3 		$408K Hold
57,689
– – ﹤0.01% 1891
2024
Q2 		$376K Buy
57,689
+11,636
+25% +$79.5K ﹤0.01% 1884
2024
Q1 		$382K Hold
46,053
– – ﹤0.01% 1820
2023
Q4 		$507K Hold
46,053
– – ﹤0.01% 1677
2023
Q3 		$387K Hold
46,053
– – ﹤0.01% 1790
2023
Q2 		$578K Buy
46,053
+1,419
+3% +$17.6K ﹤0.01% 1595
2023
Q1 		$735K Hold
44,634
– – 0.01% 1406
2022
Q4 		$667K Buy
44,634
+3,817
+9% +$73.1K 0.01% 1459
2022
Q3 		$913K Buy
40,817
+2,855
+8% +$62.6K 0.01% 1238
2022
Q2 		$636K Hold
37,962
– – ﹤0.01% 1498
2022
Q1 		$1.14M Buy
37,962
+13,536
+55% +$328K 0.01% 1254
2021
Q4 		$750K Buy
24,426
+3,157
+15% +$99.8K 0.01% 1269
2021
Q3 		$671K Hold
21,269
– – 0.01% 1358
2021
Q2 		$778K Buy
21,269
+3,713
+21% +$122K 0.01% 1315
2021
Q1 		$607K Buy
17,556
+3,826
+28% +$166K 0.01% 1412
2020
Q4 		$571K Hold
13,730
– – 0.01% 1424
2020
Q3 		$585K Buy
+13,730
New +$524K 0.01% 1287

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

MetLife Investment Management's RLAY Position: Q2 2026 in Review

MetLife Investment Management increased its Relay Therapeutics (RLAY) stake by 19% in Q2 2026, buying an estimated $219K and bringing the position to 94,122 shares worth $1.76M. The position accounts for 0.01% of the portfolio, ranked #1232.

MetLife Investment Management first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • MetLife Investment Management held 94,122 shares of Relay Therapeutics worth $1.76M as of Q2 2026.
  • MetLife Investment Management bought 15,098 Relay Therapeutics shares in Q2 2026, an estimated $219K.
  • Relay Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1232 holding.
  • MetLife Investment Management first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.